Unraveling the Role of Glucocorticoid Receptor in Inflammation and Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 616
Special Issue Editor
Interests: glucocorticoid receptor in inflammation and cancer; estrogen receptor beta in breast cancer prognosis and treatment; natural and synthetic agents for preventing and/or treating endocrine disorders; hazard assessment of endocrine-disrupting chemicals
Special Issue Information
Dear Colleagues,
Glucocorticoids (GCs) are steroid hormones that regulate a variety of physiological processes, including development, metabolism, homeostasis, immune response, and apoptosis in a cell-specific manner. The biological actions of GCs are mediated through the ubiquitously expressed glucocorticoid receptor (GR), a ligand-inducible transcription factor that is activated upon GC binding and regulates the transcription of hundreds of target genes.
GC-activated GR is implicated in various diseases, ranging from inflammatory and metabolic disorders to cancer. GCs are widely used as potent anti-inflammatory drugs for the treatment of inflammatory and autoimmune diseases. Under physiological conditions, GCs also exert pro-inflammatory effects. These apparently opposite actions seem to work together to prepare the immune response under stress conditions (pro-inflammatory), subsequently controlling the response (anti-inflammatory) and restoring homeostasis.
Inflammation is known to predispose the development and promote the progression of various types of cancer. The glucocorticoid regulation of tumor-promoting inflammation and anti-tumor immunity affects cancer development. Despite the extensive clinical use of GCs to alleviate the side effects of chemotherapy, the role of GR in cancer initiation, progression, and therapy remains elusive. GCs have been used for the treatment of various hematological cancers; however, their role in different types of solid cancers is not clearly defined. GC signaling through GR may either suppress or promote tumor development in a cancer type-specific manner.
The clinical use of GC is often accompanied with adverse side effects. Nevertheless, the therapeutic usage of GCs is continuously rising. At present, there is an unmet need for novel selective GR agonists/modulators (SEGRA/SEGRM) favoring the therapeutic action of GCs over the undesirable side effects. Such ligands could improve the clinical performance of long-term treatments with GCs, where adverse side effects should be taken into consideration.
This Special Issue aims to unravel the role of GCs and GR in inflammation and cancer initiation, progression, and treatment. New studies are expected to shed light on the molecular and cellular mechanisms underlying the anti-/pro-inflammatory and tumor-suppressive/oncogenic action of GR. Studies on novel agonists/modulators with an improved therapeutic index as compared to classical GCs are also welcome.
Dr. Dimitra Mitsiou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glucocorticoids
- glucocorticoid receptor
- inflammation
- anti-inflammatory action
- pro-inflammatory action
- cancer
- tumor-promoting inflammation
- onco-suppressive action
- oncogenic action
- selective glucocorticoid receptor agonists/modulators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
